DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lamotrigine (Lamotrigine) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The following adverse reactions are described in more detail in the Warnings and Precautions  section of the label:

  • Serious skin rashes [see Warnings and Precautions ] 
  • Multiorgan hypersensitivity reactions and organ failure [see Warnings and Precautions ( 5.2 )] 
  • Blood dyscrasias [see Warnings and Precautions ] 
  • Suicidal behavior and ideation [see Warnings and Precautions] 
  • Aseptic Meningitis [see Warnings and Precautions (5.6 )] 

  • Withdrawal seizures [see Warnings and Precautions ]

  • Status epilepticus [see Warnings and Precautions]  

  • Sudden unexplained death in epilepsy [see Warnings and Precautions ]

Clinical Trials

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Lamotrigine has been evaluated for safety in patients with epilepsy and in patients with Bipolar I Disorder. Adverse reactions reported for each of these patient populations are provided below. Excluded are adverse reactions considered too general to be informative and those not reasonably attributable to the use of the drug.

Epilepsy:  Most Common Adverse Reactions in All Clinical Studies: Adjunctive Therapy in Adults With Epilepsy: The most commonly observed (≥5% for Lamotrigine and more common on drug than placebo) adverse reactions seen in association with Lamotrigine during adjunctive therapy in adults and not seen at an equivalent frequency among placebo-treated patients were: dizziness, ataxia, somnolence, headache, diplopia, blurred vision, nausea, vomiting, and rash. Dizziness, diplopia, ataxia, blurred vision, nausea, and vomiting were dose-related. Dizziness, diplopia, ataxia, and blurred vision occurred more commonly in patients receiving carbamazepine with Lamotrigine than in patients receiving other AEDs with Lamotrigine. Clinical data suggest a higher incidence of rash, including serious rash, in patients receiving concomitant valproate than in patients not receiving valproate [see Warnings and Precautions] .

Approximately 11% of the 3,378 adult patients who received Lamotrigine as adjunctive therapy in premarketing clinical trials discontinued treatment because of an adverse experience. The adverse reactions most commonly associated with discontinuation were rash (3.0%), dizziness (2.8%), and headache (2.5%).

In a dose-response study in adults, the rate of discontinuation of Lamotrigine for dizziness, ataxia, diplopia, blurred vision, nausea, and vomiting was dose-related.

Monotherapy in Adults With Epilepsy: The most commonly observed (≥5% for Lamotrigine and more common on drug than placebo) adverse reactions seen in association with the use of Lamotrigine during the monotherapy phase of the controlled trial in adults not seen at an equivalent rate in the control group were vomiting, coordination abnormality, dyspepsia, nausea, dizziness, rhinitis, anxiety, insomnia, infection, pain, weight decrease, chest pain, and dysmenorrhea. The most commonly observed (≥5% for Lamotrigine and more common on drug than placebo) adverse reactions associated with the use of Lamotrigine during the conversion to monotherapy (add-on) period, not seen at an equivalent frequency among low-dose valproate-treated patients, were dizziness, headache, nausea, asthenia, coordination abnormality, vomiting, rash, somnolence, diplopia, ataxia, accidental injury, tremor, blurred vision, insomnia, nystagmus, diarrhea, lymphadenopathy, pruritus, and sinusitis. 

Approximately 10% of the 420 adult patients who received Lamotrigine as monotherapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were rash (4.5%), headache (3.1%), and asthenia (2.4%).

Adjunctive Therapy in Pediatric Patients With Epilepsy: The most commonly observed (≥5% for Lamotrigine and more common on drug than placebo) adverse reactions seen in association with the use of Lamotrigine as adjunctive treatment in pediatric patients 2 to 16 years of age and not seen at an equivalent rate in the control group were infection, vomiting, rash, fever, somnolence, accidental injury, dizziness, diarrhea, abdominal pain, nausea, ataxia, tremor, asthenia, bronchitis, flu syndrome, and diplopia.

In 339 patients 2 to 16 years of age with partial seizures or generalized seizures of Lennox-Gastaut syndrome, 4.2% of patients on Lamotrigine and 2.9% of patients on placebo discontinued due to adverse reactions. The most commonly reported adverse reaction that led to discontinuation of Lamotrigine was rash.

Approximately 11.5% of the 1,081 pediatric patients 2 to 16 years of age who received Lamotrigine as adjunctive therapy in premarketing clinical trials discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were rash (4.4%), reaction aggravated (1.7%), and ataxia (0.6%).

Controlled Adjunctive Clinical Studies in Adults With Epilepsy: Table 8 lists treatment-emergent adverse reactions that occurred in at least 2% of adult patients with epilepsy treated with Lamotrigine in placebo-controlled trials and were numerically more common in the patients treated with Lamotrigine. In these studies, either Lamotrigine or placebo was added to the patient's current AED therapy. Adverse reactions were usually mild to moderate in intensity.

Table 8. Treatment-Emergent Adverse Reaction Incidence in Placebo-Controlled Adjunctive Trials in Adult Patients With Epilepsy 1 (Adverse reactions in at least 2% of patients treated with Lamotrigine and numerically more frequent than in the placebo group.)
Body System/Adverse Experience Percent of Patients Receiving Adjunctive Lamotrigine
(n = 711)
Percent of Patients Receiving Adjunctive Placebo
(n = 419)
Body as a whole
   Headache 29 19
   Flu syndrome 7 6
   Fever 6 4
   Abdominal pain 5 4
   Neck pain 2 1
   Reaction aggravated 
   (seizure exacerbation)
2 1
Digestive
   Nausea 19 10
   Vomiting 9 4
   Diarrhea 6 4
   Dyspepsia 5 2
   Constipation 4 3
   Anorexia 2 1
Musculoskeletal
   Arthralgia 2 0
Nervous
   Dizziness 38 13
   Ataxia 22 6
   Somnolence 14 7
   Incoordination 6 2
   Insomnia 6 2
   Tremor 4 1
   Depression 4 3
   Anxiety 4 3
   Convulsion 3 1
   Irritability 3 2
   Speech disorder 3 0
   Concentration disturbance 2 1
Respiratory
   Rhinitis 14 9
   Pharyngitis 10 9
   Cough increased 8 6
Skin and appendages
   Rash 10 5
   Pruritus 3 2
Special senses
   Diplopia 28 7
   Blurred vision 16 5
   Vision abnormality 3 1
Urogenital
   Female patients only (n = 365) (n = 207)
   Dysmenorrhea 7 6
   Vaginitis 4 1
   Amenorrhea 2 1

1 Patients in these adjunctive studies were receiving 1 to 3 of the following concomitant AEDs (carbamazepine, phenytoin, phenobarbital, or primidone) in addition to Lamotrigine or placebo. Patients may have reported multiple adverse reactions during the study or at discontinuation; thus, patients may be included in more than one category.

In a randomized, parallel study comparing placebo and 300 and 500 mg/day of Lamotrigine, some of the more common drug-related adverse reactions were dose-related (see Table 9).

Table 9. Dose-Related Adverse Reactions From a Randomized, Placebo-Controlled Adjunctive Trial in Adults With Epilepsy
Percent of Patients Experiencing Adverse Reactions
Adverse Reaction Placebo (n = 73) Lamotrigine 300 mg
(n = 71)
Lamotrigine 500 mg
(n = 72)
Ataxia 10 10 28 1 2
Blurred vision 10 11 25
Diplopia 8 24 49
Dizziness 27 31 54
Nausea 11 18 25
Vomiting 4 11 18

1 Significantly greater than placebo group (p < 0.05).
2 Significantly greater than group receiving Lamotrigine 300 mg (p < 0.05).

The overall adverse experience profile for Lamotrigine was similar between females and males, and was independent of age. Because the largest non-Caucasian racial subgroup was only 6% of patients exposed to Lamotrigine in placebo-controlled trials, there are insufficient data to support a statement regarding the distribution of adverse reaction reports by race. Generally, females receiving either Lamotrigine as adjunctive therapy or placebo were more likely to report adverse reactions than males. The only adverse reaction for which the reports on Lamotrigine were greater than 10% more frequent in females than males (without a corresponding difference by gender on placebo) was dizziness (difference = 16.5%). There was little difference between females and males in the rates of discontinuation of Lamotrigine for individual adverse reactions.

Controlled Monotherapy Trial in Adults With Partial Seizures: Table 10 lists treatment-emergent adverse reactions that occurred in at least 5% of patients with epilepsy treated with monotherapy with Lamotrigine in a double-blind trial following discontinuation of either concomitant carbamazepine or phenytoin not seen at an equivalent frequency in the control group.

Table 10. Treatment-Emergent Adverse Reaction Incidence in Adults With Partial Seizures in a Controlled Monotherapy Trial 1 (Adverse reactions in at least 5% of patients treated with Lamotrigine and numerically more frequent than in the valproate group.)
Body System/Adverse Reaction Percent of Patients Receiving Lamotrigine as Monotherapy 2
(n = 43)
Percent of Patients Receiving Low-Dose Valproate 3 Monotherapy
(n = 44)
Body as a whole
    Pain 5 0
    Infection 5 2
    Chest pain 5 2
Digestive
    Vomiting 9 0
    Dyspepsia 7 2
    Nausea 7 2
Metabolic and nutritional
    Weight decrease 5 2
    Nervous
    Coordination abnormality 7 0
    Dizziness 7 0
    Anxiety 5 0
    Insomnia 5 2
Respiratory
    Rhinitis 7 2
    Urogenital (female patients only) (n = 21) (n = 28)
    Dysmenorrhea 5 0

1 Patients in these studies were converted to Lamotrigine or valproate monotherapy from adjunctive therapy with carbamazepine or phenytoin. Patients may have reported multiple adverse reactions during the study; thus, patients may be included in more than one category.
2 Up to 500 mg/day.
3 1,000 mg/day.

Adverse reactions that occurred with a frequency of less than 5% and greater than 2% of patients receiving Lamotrigine and numerically more frequent than placebo were:

Body as a Whole: Asthenia, fever.

Digestive: Anorexia, dry mouth, rectal hemorrhage, peptic ulcer.

Metabolic and Nutritional: Peripheral edema.

Nervous System: Amnesia, ataxia, depression, hypesthesia, libido increase, decreased reflexes, increased reflexes, nystagmus, irritability, suicidal ideation.

Respiratory: Epistaxis, bronchitis, dyspnea.

Skin and Appendages: Contact dermatitis, dry skin, sweating.

Special Senses: Vision abnormality.

Incidence in Controlled Adjunctive Trials in Pediatric Patients With Epilepsy: Table 11 lists adverse reactions that occurred in at least 2% of 339 pediatric patients with partial seizures or generalized seizures of Lennox-Gastaut syndrome, who received Lamotrigine up to 15 mg/kg/day or a maximum of 750 mg/day. Reported adverse reactions were classified using COSTART terminology.

Table 11. Treatment-Emergent Adverse Reaction Incidence in Placebo-Controlled Adjunctive Trials in Pediatric Patients With Epilepsy (Adverse reactions in at least 2% of patients treated with Lamotrigine and numerically more frequent than in the placebo group.)
Body System/Adverse Reaction Percent of Patients
Receiving Lamotrigine
(n = 168)
Percent of Patients
Receiving Placebo
(n = 171)
Body as a whole
    Infection 20 17
    Fever 15 14
    Accidental injury 14 12
    Abdominal pain 10 5
    Asthenia 8 4
    Flu syndrome 7 6
    Pain 5 4
    Facial edema 2 1
    Photosensitivity 2 0
Cardiovascular
    Hemorrhage 2 1
Digestive
    Vomiting 20 16
    Diarrhea 11 9
    Nausea 10 2
    Constipation 4 2
    Dyspepsia 2 1
Hemic and lymphatic
    Lymphadenopathy 2 1
Metabolic and nutritional
    Edema 2 0
Nervous system
    Somnolence 17 15
    Dizziness 14 4
    Ataxia 11 3
    Tremor 10 1
    Emotional lability 4 2
    Gait abnormality 4 2
    Thinking abnormality 3 2
    Convulsions 2 1
    Nervousness 2 1
    Vertigo 2 1
Respiratory
    Pharyngitis 14 11
    Bronchitis 7 5
    Increased cough 7 6
    Sinusitis 2 1
    Bronchospasm 2 1
Skin
    Rash 14 12
    Eczema 2 1
    Pruritus 2 1
Special senses
    Diplopia 5 1
    Blurred vision 4 1
    Visual abnormality 2 0
Urogenital
    Male and female patients
    Urinary tract infection 3 0

Bipolar Disorder: The most commonly observed (≥5%) treatment-emergent adverse reactions seen in association with the use of Lamotrigine as monotherapy (100 to 400 mg/day) in adult patients (≥18 years of age) with Bipolar Disorder in the 2 double-blind, placebo-controlled trials of 18 months’ duration, and numerically more frequent than in placebo-treated patients are included in Table 12. Adverse reactions that occurred in at least 5% of patients and were numerically more common during the dose-escalation phase of Lamotrigine in these trials (when patients may have been receiving concomitant medications) compared with the monotherapy phase were: headache (25%), rash (11%), dizziness (10%), diarrhea (8%), dream abnormality (6%), and pruritus (6%).

During the monotherapy phase of the double-blind, placebo-controlled trials of 18 months' duration, 13% of 227 patients who received Lamotrigine (100 to 400 mg/day), 16% of 190 patients who received placebo, and 23% of 166 patients who received lithium discontinued therapy because of an adverse reaction. The adverse reactions which most commonly led to discontinuation of Lamotrigine were rash (3%) and mania/hypomania/mixed mood adverse reactions (2%). Approximately 16% of 2,401 patients who received Lamotrigine (50 to 500 mg/day) for Bipolar Disorder in premarketing trials discontinued therapy because of an adverse reaction; most commonly due to rash (5%) and mania/hypomania/mixed mood adverse reactions (2%).

The overall adverse event profile for Lamotrigine was similar between females and males, between elderly and nonelderly patients, and among racial groups.

Table 12. Treatment-Emergent Adverse Reaction Incidence in 2 Placebo-Controlled Trials in Adults With Bipolar I Disorder 1 (Adverse reactions in at least 5% of patients treated with Lamotrigine as monotherapy and numerically more frequent than in the placebo group.)
Body System/Adverse

Reaction

Percent of Patients Receiving
Lamotrigine (n = 227)
Percent of Patients Receiving Placebo
(n = 190)
General    
    Back pain 8 6
    Fatigue 8 5
    Abdominal pain 6 3
Digestive    
    Nausea 14 11
    Constipation 5 2
    Vomiting 5 2
Nervous System    
    Insomnia 10 6
    Somnolence 9 7
    Xerostomia (dry mouth) 6 4
Respiratory    
    Rhinitis 7 4
    Exacerbation of cough 5 3
    Pharyngitis 5 4
Skin    
    Rash (nonserious) 2 7 5

1 Patients in these studies were converted to Lamotrigine (100 to 400 mg/day) or placebo monotherapy from add-on therapy with other psychotropic medications. Patients may have reported multiple adverse reactions during the study; thus, patients may be included in more than one category.
2 In the overall bipolar and other mood disorders clinical trials, the rate of serious rash was 0.08% (1 of 1,233) of adult patients who received Lamotrigine as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received Lamotrigine as adjunctive therapy [see Warnings and Precautions ] .

These adverse reactions were usually mild to moderate in intensity. Other reactions that occurred in 5% or more patients but equally or more frequently in the placebo group included: dizziness, mania, headache, infection, influenza, pain, accidental injury, diarrhea, and dyspepsia.

Adverse reactions that occurred with a frequency of less than 5% and greater than 1% of patients receiving Lamotrigine and numerically more frequent than placebo were:

General: Fever, neck pain.

Cardiovascular: Migraine.

Digestive: Flatulence

Metabolic and Nutritional: Weight gain, edema.

Musculoskeletal: Arthralgia, myalgia.

Nervous System: Amnesia, depression, agitation, emotional lability, dyspraxia, abnormal thoughts, dream abnormality, hypoesthesia.

Respiratory: Sinusitis.

Urogenital: Urinary frequency.

Adverse Reactions Following Abrupt Discontinuation: In the 2 maintenance trials, there was no increase in the incidence, severity or type of adverse reactions in Bipolar Disorder patients after abruptly terminating therapy with Lamotrigine. In clinical trials in patients with Bipolar Disorder, 2 patients experienced seizures shortly after abrupt withdrawal of Lamotrigine. However, there were confounding factors that may have contributed to the occurrence of seizures in these bipolar patients [see Warnings and Precautions] .

Mania/Hypomania/Mixed Episodes: During the double-blind, placebo-controlled clinical trials in Bipolar I Disorder in which patients were converted to monotherapy with Lamotrigine (100 to 400 mg/day) from other psychotropic medications and followed for up to 18 months, the rates of manic or hypomanic or mixed mood episodes reported as adverse reactions were 5% for patients treated with Lamotrigine (n = 227), 4% for patients treated with lithium (n = 166), and 7% for patients treated with placebo (n = 190). In all bipolar controlled trials combined, adverse reactions of mania (including hypomania and mixed mood episodes) were reported in 5% of patients treated with Lamotrigine (n = 956), 3% of patients treated with lithium (n = 280), and 4% of patients treated with placebo (n = 803).

Other Adverse Reactions Observed in All Clinical Trials

Lamotrigine has been administered to 6,694 individuals for whom complete adverse reaction data was captured during all clinical trials, only some of which were placebo controlled. During these trials, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of adverse reactions were grouped into a smaller number of standardized categories using modified COSTART dictionary terminology. The frequencies presented represent the proportion of the 6,694 individuals exposed to Lamotrigine who experienced an event of the type cited on at least one occasion while receiving Lamotrigine. All reported adverse reactions are included except those already listed in the previous tables or elsewhere in the labeling, those too general to be informative, and those not reasonably associated with the use of the drug.

Adverse reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse reactions are defined as those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients; rare adverse reactions are those occurring in fewer than 1/1,000 patients.

Body as a Whole:  Infrequent: Allergic reaction, chills, and malaise.

Cardiovascular System: Infrequent: Flushing, hot flashes, hypertension, palpitations, postural hypotension, syncope, tachycardia, and vasodilation.

Dermatological:  Infrequent: Acne, alopecia, hirsutism, maculopapular rash, skin discoloration, and urticaria. Rare: Angioedema, erythema, exfoliative dermatitis, fungal dermatitis, herpes zoster, leukoderma, multiforme erythema, petechial rash, pustular rash, Stevens-Johnson syndrome, and vesiculobullous rash.

Digestive System:  Infrequent: Dysphagia, eructation, gastritis, gingivitis, increased appetite, increased salivation, liver function tests abnormal, and mouth ulceration. Rare: Gatrointestinal hemorrhage, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hemorrhagic colitis, hepatitis, melena, stomach ulcer, stomatitis, and tongue edema.

Endocrine System:  Rare: Goiter and hypothyroidism.

Hematologic and Lymphatic System: Infrequent: Ecchymosis and leukopenia. Rare: Anemia, eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis, lymphocytosis, macrocytic anemia, petechia, and thrombocytopenia.

Metabolic and Nutritional Disorders: Infrequent: Aspartate transaminase increased. Rare: Alcohol intolerance, alkaline phosphatase increase, alanine transaminase increase, bilirubinemia, general edema, gamma glutamyl transpeptidase increase, and hyperglycemia.

Musculoskeletal System: Infrequent: Arthritis, leg cramps, myasthenia, and twitching. Rare: Bursitis, muscle atrophy, pathological fracture, and tendinous contracture.

Nervous System: Frequent: Confusion and paresthesia. Infrequent: Akathisia, apathy, aphasia, CNS depression, depersonalization, dysarthria, dyskinesia, euphoria, hallucinations, hostility, hyperkinesia, hypertonia, libido decreased, memory decrease, mind racing, movement disorder, myoclonus, panic attack, paranoid reaction, personality disorder, psychosis, sleep disorder, stupor, and suicidal ideation. Rare: Choreoathetosis, delirium, delusions, dysphoria, dystonia, extrapyramidal syndrome, faintness, grand mal convulsions, hemiplegia, hyperalgesia, hyperesthesia, hypokinesia, hypotonia, manic depression reaction, muscle spasm, neuralgia, neurosis, paralysis, and peripheral neuritis.

Respiratory System:  Infrequent: Yawn. Rare: Hiccup and hyperventilation.

Special Senses: Frequent: Amblyopia. Infrequent: Abnormality of accommodation, conjunctivitis, dry eyes, ear pain, photophobia, taste perversion, and tinnitus. Rare: Deafness, lacrimation disorder, oscillopsia, parosmia, ptosis, strabismus, taste loss, uveitis, and visual field defect.

Urogenital System: Infrequent: Abnormal ejaculation, hematuria, impotence, menorrhagia, polyuria, and urinary incontinence. Rare: Acute kidney failure, anorgasmia, breast abscess, breast neoplasm, creatinine increase, cystitis, dysuria, epididymitis, female lactation, kidney failure, kidney pain, nocturia, urinary retention, and urinary urgency.

Postmarketing Experience

The following adverse events (not listed above in clinical trials or other sections of the prescribing information) have been identified during postapproval use of Lamotrigine. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic: Agranulocytosis, hemolytic anemia.

Gastrointestinal: Esophagitis.

Hepatobiliary Tract and Pancreas: Pancreatitis.

Immunologic: Lupus-like reaction, vasculitis.

Lower Respiratory: Apnea.

Musculoskeletal: Rhabdomyolysis has been observed in patients experiencing hypersensitivity reactions.

Neurology: Exacerbation of Parkinsonian symptoms in patients with pre-existing Parkinson’s disease, tics.

Non-site Specific: Progressive immunosuppression.



REPORTS OF SUSPECTED LAMOTRIGINE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Lamotrigine. The information is not vetted and should not be considered as verified clinical evidence.

Possible Lamotrigine side effects / adverse reactions in 51 year old female

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 51 year old female weighing 88.0 kg (193.6 pounds)

Reactions: Blood Pressure Increased

Suspect drug(s):
Lamotrigine

Other drugs received by patient: Lamotrigine; Effexor XR; Nexium; Adderall -Generic



Possible Lamotrigine side effects / adverse reactions in 10 year old female

Reported by a individual with unspecified qualification from United States on 2011-10-03

Patient: 10 year old female

Reactions: Dysarthria, Drooling, Fatigue, Medication Error, Hypophagia, Gait Disturbance, Posture Abnormal, Convulsion

Suspect drug(s):
Topiramate
    Dosage: (25 mg),oral
    Administration route: Oral

Lamotrigine
    Dosage: (25 mg),oral
    Administration route: Oral



Possible Lamotrigine side effects / adverse reactions in 48 year old female

Reported by a consumer/non-health professional from United States on 2011-10-03

Patient: 48 year old female

Reactions: Skin Exfoliation, Drug Rash With Eosinophilia and Systemic Symptoms

Adverse event resulted in: hospitalization

Suspect drug(s):
Lamotrigine
    Dosage: 50 mg; 100 mg; qd
    Indication: Depression
    End date: 2011-08-22

Lamotrigine
    Dosage: 50 mg; 100 mg; qd
    Indication: Affective Disorder
    End date: 2011-08-22

Lamotrigine
    Dosage: 50 mg; 100 mg; qd
    Indication: Depression
    Start date: 2011-08-23
    End date: 2011-08-25

Lamotrigine
    Dosage: 50 mg; 100 mg; qd
    Indication: Affective Disorder
    Start date: 2011-08-23
    End date: 2011-08-25

Lamotrigine
    Dosage: 100 mg; qd; po
    Administration route: Oral
    Indication: Affective Disorder
    Start date: 2011-08-26
    End date: 2011-08-30

Lamotrigine
    Dosage: 100 mg; qd; po
    Administration route: Oral
    Indication: Depression
    Start date: 2011-08-26
    End date: 2011-08-30

Other drugs received by patient: Senna; Ramipril; Synthroid; Coumadin; Colace; Coreg; Celexa



See index of all Lamotrigine side effect reports >>

Drug label data at the top of this Page last updated: 2013-01-18

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017